10/25/2007 1:34:35 PM
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. (Nasdaq: SEPR) today announced that it presented safety and efficacy data from several studies of BROVANA™ (arformoterol tartrate) Inhalation Solution at CHEST 2007, the annual meeting of the American College of Chest Physicians, in Chicago.
The Effect of Twice-Daily Nebulized Arformoterol on QTC in Subjects With COPD
This four-week, placebo-controlled, randomized, double-blind, multicenter, parallel-group, dose-ranging study evaluated changes in QTc interval in patients with chronic obstructive pulmonary disease (COPD) who were administered arformoterol at various doses, or placebo. Patients were divided into Part A (n=215) and were administered arformoterol 5 mcg, 15 mcg, or 25 mcg or placebo twice daily for two weeks, and subsequently re-randomized in Part B (n=191) and administered arformoterol 15 mcg, 25 mcg, or 50 mcg or placebo once daily for two weeks. Two models were used to calculate QTc from results of electrocardiograms (ECGs) for each of the patients in the study. Based on the data analyzed in this study, dosing with arformoterol did not prolong cardiac repolarization.